We use cookies to understand how you use our site and to improve your experience. Please refer to our Terms and Conditions and Privacy Policy for more information about the cookies we use and how we protect your privacy.
Camel IgE
Test Code: 521910
Clinical Utility
This assay is used to detect allergen specific-IgE using an enzyme immunoassay (EIA). In vitro allergy testing is the primary testing mode for allergy diagnosis.
Procedure
The test method is an enzyme immunoassay (EIA). Allergens are covalently coupled to the cellulose paper discs via the APT method. Alkaline phosphatase (AP) labelled anti-IgE is used to quantify the patient's specific IgE. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
2-3 business days from receipt of specimen
| Specimen Type | Order Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| Serum | 521910 | 86003 | Yes | 0.5 mL (min. 340uL) | See Scoring Guide |
|
Scoring System for the Allergen-specific IgE EIA.
| Class | IgE (kU/L) | Comment |
| 0 | <0.35 | Below Detection |
| 1 | 0.35 - 0.69 | Low Positive |
| 2 | 0.70 - 3.49 | Moderate Positive |
| 3 | 3.50 - 17.49 | Positive |
| 4 | 17.50 - 49.99 | Strong Positive |
| 5 | 50.00 - 99.99 | Very Strong Positive |
| 6 | >99.99 | Very Strong Positive |
Causes for Rejection
Lipemic samples may lead to rejection.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References
Position Statement 12 April 1990 published in Immunology and Allergy Practice.
Project Hope, Center for Health Affairs: "The Cost Implications and Cost Effectiveness of Allergy in Vitro Diagnostic Testing.", October 1988.
Hamilton R, Adkinson NF. Quantitation of allergen-specific IgE in serum using the radioallergosorben test. (Review) J Clin Immunoassay. 1983;6:147-54.
Kelso JM, Sodhi N, Gosselin VA, Yunginger JW. Diagnostic performance characteristics of the standard Phadebas RAST, modified RAST, and Pharmacia CAP system vs skin testing. Ann Allergy. 1991 Nov;67(5):511-4.
Williams PB, Dolen WK, Koepke JW, Selner JC. Comparison of skin testing and three in vitro assays for specific IgE in the clinical evaluation of immediate hypersensitivity. Ann Allergy. 1992 Jan;68(1):34-45.
Selner JC, Sullivan TJ, Ahlstedt S, et al. Current issues relating to in vitro testing for allergen-specific IgE: a workshop report. Ann Allergy Asthma Immunol. 1999 May;82(5):407-12.
Poon AW, Goodman CS, Rubin RJ. In vitro and skin testing for allergy: comparable clinical utility and costs. Am J Manag Care. 1998 Jul;4(7):969-85.
Sampson HA, Ho DG. Relationships between food-specific IgE concentration and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol. 1997 Oct;100(4):444-51.
Williams PB, Barnes JH, Szeinbach SL, Sullivan TJ. Analytical precision and accuracy of commercial immunoassays for specific IgE: establishing a standard. J Allergy Clin Immunol. 2000 Jun;105(6 Pt1):1221-30.
Szeinbach SL, Barnes JH, Sullivan TJ, Williams PB. Precision and accuracy of commercial laboratories ability to classify positive and/or negative allergen-specific IgE results. Ann Allergy Asthma Immunol. 2001 Apr:86(4):373-81.